Home-Shanghai Leadingtac Pharmaceutical Co., Ltd.

Pioneering
New Modality

Transforming
Novel Medication

Pioneering New Modality，
Transforming Novel Medication

Discovery and development of First-in-class/Best-in-class small molecule innovative drug

Novel discovery platforms of targeted protein degradation (TPD), with a commitment on areas of autoimmunity and oncology, leveraging new unmet medical needs and the synergistic combinations to transform patients life.

More

LeadingTac’s first protein degrader has commenced a Phase I clinical study in China in June 2024

More

Leadingtac is dedicated to the discovery and development of nano-SPUD® innovative drug to advance the precision protein degrader system

More

Leadingtac management team has most members from both Chinese, American and European biotech and pharmaceutical companies. Excelling their perspectives and expertise in the field of small molecule drug development, specifically the in the field of protein degradation

More

Science and Technology

We will always share with you a little bit of what we do

Leadingtac Secures Over $14 million Series A Financing secures for IRAK4 degraders

Big congratulations to Dr. Zhengqing Ye of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024

Big congratulations to Dr. Yan Shuang of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024

Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader

LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa

Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023

Leadingtac Secures Over $14 million Series A Financing secures for IRAK4 degraders

Big congratulations to Dr. Zhengqing Ye of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024

Big congratulations to Dr. Yan Shuang of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024

Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader

LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa

Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023

Blaze a new path in the development of targeted protein degradation drugs.

Since 2019

Major Milestones

Management Team

Industry Information

Employment Philosophy

Development Space

Room 501, 781 Cailun Road, Pilot Free Trade Zone, Pudong, Shanghai, China

+86-(0)21-50561622

hr@leadingtac.com/yxie@leadingtac.com

Company Mailbox

hr@leadingtac.com
yxie@leadingtac.com

Official Account

Copyright © 2024 Shanghai Leadingtac Pharmaceutical Co., Ltd. All Rights Reserved. 沪ICP备2022020812号-1

Design by jijin